New Generic Prostate Cancer Drug in Canada Aims to Lower Costs, Expand Access

BOUCHERVILLE, QC – March 16, 2026 – Canadian patients and healthcare providers have a new, more affordable option in the fight against prostate cancer. JAMP Pharma Group, a prominent Canadian pharmaceutical company, today announced the launch of PrJAMP Enzalutamide, a generic version of the widely used oncology medication Xtandi®. This launch is poised to increase competition, lower treatment costs, and improve access to a critical therapy for various stages of prostate cancer.

Enzalutamide is an orally administered antiandrogen that has become a cornerstone in treating prostate cancer by blocking the hormonal signals that fuel cancer cell growth. The introduction of a generic alternative by the Boucherville-based company marks a significant development for Canada's healthcare system, which continually grapples with the high cost of specialty drugs.

Shifting the Market and Healthcare Economics

The arrival of PrJAMP Enzalutamide signals a significant shift in the market for this crucial prostate cancer treatment. The brand-name drug, Xtandi®, marketed by Astellas Pharma Canada Inc., has been a standard of care but at a substantial cost. The introduction of generic alternatives is a key mechanism for controlling healthcare expenditures, and JAMP Pharma's launch is expected to intensify price competition.

This is not the first generic enzalutamide to enter the Canadian market; JAMP's product is the second, a fact that typically accelerates price reductions and expands availability. For provincial drug plans and private insurers, this competition can lead to substantial savings, freeing up resources that can be reallocated to other essential healthcare services. For patients, it can mean lower out-of-pocket costs and reduced financial barriers to accessing a life-extending therapy.

"The launch of PrJAMP Enzalutamide marks an important step in our mission to improve accessibility to important oncology care in Canada," said Louis Pilon, President and CEO of JAMP Pharma Group, in a statement. "By adding this 12th product to our oncology portfolio, we are not only offering a lower-cost therapeutic option for prostate cancer patients but also reaffirming our role as a partner of choice for healthcare professionals."

JAMP's Strategic Expansion in Specialty Care

This launch is a cornerstone of JAMP Pharma Group's broader strategy to solidify its position as a leader in the Canadian specialty pharmaceutical sector. The company, which claims to offer the largest selection of generic medications in the country with nearly 350 molecules, has been aggressively expanding its footprint in complex treatments like oncology.

PrJAMP Enzalutamide becomes the 12th product in the company's growing oncology portfolio. This move is complemented by the company's recent strategic investments in domestic manufacturing. In 2024, JAMP Pharma acquired a manufacturing facility in Lévis, Québec, a move aimed at strengthening the Canadian drug supply chain and increasing domestic production capabilities. This investment underscores a commitment to ensuring a stable and continuous supply of critical medications for Canadians.

The company’s integrated approach combines affordable generics with robust patient support, a strategy articulated by Amélie Faubert, Senior Vice President of Institutional Affairs & Specialty Products. "The introduction of PrJAMP Enzalutamide is part of our commitment to offering the Canadian market complex generic solutions that meet critical needs in oncology," Faubert explained. She noted that all oncology products are now supported by a single, unified patient support program.

Beyond the Price Tag: Comprehensive Patient Support

For patients navigating a prostate cancer diagnosis, access to medication is only one part of the journey. Recognizing this, JAMP Pharma is bundling the new generic with its comprehensive patient support program, JAMP Care™. This program is designed to provide holistic support that extends well beyond the pharmacy counter.

PrJAMP Enzalutamide is indicated for a wide range of prostate cancer stages, including non-metastatic and metastatic castration-sensitive prostate cancer (nmCSPC and mCSPC) and castration-resistant prostate cancer (nmCRPC and mCRPC). The JAMP Care™ program offers these patients a suite of specialized services, including nutritional counseling, kinesiology, sex therapy, and access to social workers. This integrated support structure aims to help patients manage the physical and emotional challenges of their treatment journey.

"Through our JAMP Care™ program, we ensure that every patient benefits from personalized guidance and specialized support throughout their treatment journey," Pilon stated. This approach addresses the complex needs of oncology patients, helping them navigate reimbursement processes, adhere to treatment protocols, and maintain the best possible quality of life.

The Clinical Role of Enzalutamide

Enzalutamide functions by blocking the androgen receptor signaling pathway, a key driver of prostate cancer growth. Its effectiveness across multiple disease states has made it an invaluable tool for oncologists. The availability of PrJAMP Enzalutamide in 40 mg oral capsules provides a bioequivalent and more affordable alternative for this established therapy.

The medication is used in patients with castration-sensitive cancer, where the disease still responds to hormone level reduction, as well as in castration-resistant stages, where the cancer progresses despite low testosterone levels. The availability of a generic version ensures that this effective treatment can be more widely utilized without imposing an unsustainable financial burden on the healthcare system or individual patients. As with any prescription medication, patients and healthcare professionals are advised to consult the official product monograph for complete prescribing information, including dosage, administration, and safety warnings.